{
  "query": "adverse chemotherapy cycles death",
  "studies": {
    "protocolSection": [
      {
        "identificationModule": {
          "nctId": "NCT02468557",
          "briefTitle": "Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-07-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-04-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Previously Untreated Pancreatic Ductal Adenocarcinoma", "Relapsed/Refractory Pancreatic Ductal Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01005680",
          "briefTitle": "A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-11"
          },
          "completionDateStruct": {
            "date": "2012-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 256,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06817161",
          "briefTitle": "Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-04-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Carcinoma", "First Line Chemotherapy", "Digestive System Disorders"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 116,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06662669",
          "briefTitle": "YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-11-30",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-08-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04524689",
          "briefTitle": "Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-10-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 57,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04905810",
          "briefTitle": "Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-02-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Recurrent Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06389760",
          "briefTitle": "Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-10-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 57,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03783442",
          "briefTitle": "A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-12-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-08-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Esophageal Squamous Cell Carcinoma (ESCC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 649,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01896869",
          "briefTitle": "FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-05-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Pancreatic Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 83,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01803269",
          "briefTitle": "Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-01-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-03-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Extensive Stage Small Cell Lung Cancer", "Recurrent Small Cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 29,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05247619",
          "briefTitle": "A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-06-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Cervical Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 49,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03086993",
          "briefTitle": "Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-04-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-05",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Bile Duct Cancer", "Intrahepatic Cholangiocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 295,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03963193",
          "briefTitle": "Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-06-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2021-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Gastrointestinal Neuroendocrine Tumor"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 112,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04128501",
          "briefTitle": "Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-05-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Bilineal Leukemia", "Acute Biphenotypic Leukemia", "Acute Myeloid Leukemia", "Mixed Phenotype Acute Leukemia", "T Acute Lymphoblastic Leukemia", "Therapy-Related Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 125,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02028507",
          "briefTitle": "Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-03-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-01-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 693,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00283244",
          "briefTitle": "Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-03"
          },
          "completionDateStruct": {
            "date": "2014-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 147,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "70 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06348134",
          "briefTitle": "Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2036-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "HER2-positive Breast Cancer", "Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 74,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06966232",
          "briefTitle": "Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-05-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-05-20",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Gastrointestinal Cancers"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 136,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05930665",
          "briefTitle": "Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-11-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Pleural Mesothelioma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 38,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06570811",
          "briefTitle": "Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-08-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-03-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer", "Chemotherapeutic Toxicity"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04681911",
          "briefTitle": "Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-09-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-09-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 71,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01062399",
          "briefTitle": "Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-12"
          },
          "completionDateStruct": {
            "date": "2022-05-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Brain and Central Nervous System Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 279,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03219593",
          "briefTitle": "Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-09-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Cancer", "Apatinib", "Biomarker"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02181075",
          "briefTitle": "Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-07"
          },
          "completionDateStruct": {
            "date": "2017-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Liver Tumour"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05821192",
          "briefTitle": "Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-03-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Angioimmunoblastic T-cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 34,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02393209",
          "briefTitle": "Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-06-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-01-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 14,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07220187",
          "briefTitle": "Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-05-02",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2036-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Richter Syndrome", "Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma", "Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 102,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03319901",
          "briefTitle": "Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-04-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 82,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03741244",
          "briefTitle": "TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-05-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 211,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03286244",
          "briefTitle": "Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-03-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Gastric Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 21,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03971409",
          "briefTitle": "Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-07-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Stage III Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Invasive Breast Carcinoma", "Recurrent Breast Carcinoma", "Triple-Negative Breast Carcinoma", "Unresectable Breast Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 150,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07122687",
          "briefTitle": "IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-08-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-04-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 170,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00509093",
          "briefTitle": "Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-10"
          },
          "completionDateStruct": {
            "date": "2015-04-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 32,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00975806",
          "briefTitle": "Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-09-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2011-10-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Renal Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 16,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04878107",
          "briefTitle": "SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-03-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 88,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06389292",
          "briefTitle": "A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-06-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-03-26",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 486,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01482299",
          "briefTitle": "RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-11"
          },
          "completionDateStruct": {
            "date": "2014-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Stomach Neoplasm"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01670084",
          "briefTitle": "Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-12"
          },
          "completionDateStruct": {
            "date": "2017-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["B-cell Adult Acute Lymphoblastic Leukemia", "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia", "Untreated Adult Acute Lymphoblastic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00990652",
          "briefTitle": "Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-05"
          },
          "completionDateStruct": {
            "date": "2012-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Brain and Central Nervous System Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01966003",
          "briefTitle": "Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-11-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2015-07-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-small Cell Lung Cancer Metastatic"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 642,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04575961",
          "briefTitle": "Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-02-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-03-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Cancer", "Low Grade Serous Carcinoma", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 33,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02149329",
          "briefTitle": "Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-08-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Febrile Neutropenia", "Hematological Malignancy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 276,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02989857",
          "briefTitle": "Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-02-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-05-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Cholangiocarcinoma", "Metastatic Cholangiocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 187,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02109328",
          "briefTitle": "Alisertib in Chemotherapy-pretreated Urothelial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-08-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-10-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Bladder Cancer", "Transitional Cell Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01471353",
          "briefTitle": "Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-11"
          },
          "completionDateStruct": {
            "date": "2017-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer Metastatic"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04054531",
          "briefTitle": "Study of KN046 With Chemotherapy in First Line Advanced NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-09-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05458219",
          "briefTitle": "A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-10-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Locally Advanced Unresectable or Metastatic Solid Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 470,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00823719",
          "briefTitle": "Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-05"
          },
          "completionDateStruct": {
            "date": "2011-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma, Large-Cell, Diffuse"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 61,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03637400",
          "briefTitle": "Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-11-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-06-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Methicillin-resistant Staphylococcus Aureus", "Skin Infection"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 269,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "9 Years",
          "maximumAge": "85 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02467907",
          "briefTitle": "Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-07-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-01-15",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Cervical Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 152,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05167851",
          "briefTitle": "The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 68,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02884453",
          "briefTitle": "Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-07-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Gastrooesophageal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 17,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02093000",
          "briefTitle": "A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-11-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-01-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Adenocarcinoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 201,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02446600",
          "briefTitle": "Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-03-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-08-23",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Tumor", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Tumor", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Primary Peritoneal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 579,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03811002",
          "briefTitle": "Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-07-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-02-21",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Limited Stage Lung Small Cell Carcinoma", "Stage I Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage III Lung Cancer AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 544,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03558139",
          "briefTitle": "Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-05-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-12-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Ovarian Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 34,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05901428",
          "briefTitle": "TCb vs EC-T in High Risk ER+/HER2- Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-06-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Hormone Receptor Positive HER-2 Negative Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1736,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01961544",
          "briefTitle": "Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-06"
          },
          "completionDateStruct": {
            "date": "2015-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Neoplasms", "Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 101,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "20 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01107639",
          "briefTitle": "Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-05-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-12-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Adenocarcinoma of the Gastroesophageal Junction", "Esophageal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 297,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01309828",
          "briefTitle": "Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-03"
          },
          "completionDateStruct": {
            "date": "2012-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Safety"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 153,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06210971",
          "briefTitle": "Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-02-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Rectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01662102",
          "briefTitle": "Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-12-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2013-03-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Follicular Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01899053",
          "briefTitle": "A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-06-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-04-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Nonhematologic Malignancies"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 101,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07060001",
          "briefTitle": "Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-07",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia (AML)", "Acute Myeloid Leukaemia (AML)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 112,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02502266",
          "briefTitle": "Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-05-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07-16",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 582,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06826677",
          "briefTitle": "REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-01-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Carcinoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 71,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05659628",
          "briefTitle": "CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Diffuse Large B-cell Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06385262",
          "briefTitle": "TOP 2301: Neoadjuvant Chemo for NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-03-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-10-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 126,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05902169",
          "briefTitle": "Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-01-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioblastoma", "Recurrent Glioblastoma", "GBM"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 560,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04729205",
          "briefTitle": "Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-01-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-09-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Cancer", "Gastro-Intestinal Intraepithelial Neoplasia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 9,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01399372",
          "briefTitle": "Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-09"
          },
          "completionDateStruct": {
            "date": "2022-05-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Chemotherapeutic Agent Toxicity", "Cognitive/Functional Effects", "Lymphoma", "Neurotoxicity", "Radiation Toxicity"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 91,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01904253",
          "briefTitle": "A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-07"
          },
          "completionDateStruct": {
            "date": "2014-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Cancer (SCLC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04415853",
          "briefTitle": "Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-01-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Esophageal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 416,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04921995",
          "briefTitle": "Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-04-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Nasopharyngeal Carcinoma", "Unresectable Nasopharyngeal Carcinoma", "Chemotherapy Effect", "Immunotherapy", "Stereotactic Body Radiation Therapy (SBRT)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "15 Years",
          "maximumAge": "90 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04739202",
          "briefTitle": "Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-03-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-10-26",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Adenocarcinoma", "Metastatic Gastric Cancer", "Metastatic Adenocarcinoma", "Advanced Gastric Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06387069",
          "briefTitle": "A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-04-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-09-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 316,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03268941",
          "briefTitle": "A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-09-26",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-03-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 51,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02427841",
          "briefTitle": "Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-01-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-12-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Pancreatic Adenocarcinoma", "Resectable Pancreatic Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03323151",
          "briefTitle": "A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-08-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-09-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Mantle-Cell Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05983094",
          "briefTitle": "Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer", "Neoadjuvant Therapy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 181,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02450331",
          "briefTitle": "A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-10-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-06-14",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Transitional Cell"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 809,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03496662",
          "briefTitle": "BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-08-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-07-25",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Ductal Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02602327",
          "briefTitle": "Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-01-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-08-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Colon Cancer", "Rectal Cancer", "Liver Metastases"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 21,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06415669",
          "briefTitle": "A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-05-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-05-19",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Gastric/Gastroesophageal Junction Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03031483",
          "briefTitle": "Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-04-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Mucosa Associated Lymphoid Tissue (MALT) Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 44,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06815003",
          "briefTitle": "Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-04-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-10-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Graft Versus Host Disease", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 35,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04676997",
          "briefTitle": "Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-05-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-02-28",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Triple Negative Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01890746",
          "briefTitle": "A Safety and Efficacy Study of Eltrombopag in Subjects With AML"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-09-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-01-25",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Leukaemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 148,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01501370",
          "briefTitle": "Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-01"
          },
          "completionDateStruct": {
            "date": "2012-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01704690",
          "briefTitle": "Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Esophageal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 4,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03259503",
          "briefTitle": "Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-09-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-11-05",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent T-Cell Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Hodgkin Lymphoma", "Refractory T-Cell Non-Hodgkin Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00376961",
          "briefTitle": "S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-08"
          },
          "completionDateStruct": {
            "date": "2017-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 68,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05955261",
          "briefTitle": "A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-07-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2034-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 70,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "29 Days",
          "maximumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03051373",
          "briefTitle": "Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-04-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-04-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Transitional Cell"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 108,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01763788",
          "briefTitle": "A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-05-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-10-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Squamous Non-small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 192,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05052970",
          "briefTitle": "Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-10-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-06-20",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed or Refractory Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 60,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06219317",
          "briefTitle": "Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "NSCLC Stage IV"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 136,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02134990",
          "briefTitle": "Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Non-Small-Cell Lung"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "21 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02655159",
          "briefTitle": "Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-01"
          },
          "completionDateStruct": {
            "date": "2016-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Neoplasms"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 46,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00566696",
          "briefTitle": "Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-12-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-02-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Leukemia, Acute Lymphocytic (ALL)", "Leukemia, Myeloid, Acute(AML)", "Leukemia, Myeloid, Chronic(CML)", "Juvenile Myelomonocytic Leukemia (JMML)", "Hemoglobinuria, Paroxysmal Nocturnal (PNH)", "Hodgkin Lymphoma", "Lymphoma, Non-Hodgkin (NHL)", "Myelodysplastic Syndrome (MDS)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 73,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "maximumAge": "21 Years"
        }
      }
    ],
    "protocolSection.1": [
      {
        "identificationModule": {
          "nctId": "NCT06484491",
          "briefTitle": "IMPT Dose Escalation for NSCLC (HyDose)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-09-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-10-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Non-Small-Cell Lung"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 87,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06187597",
          "briefTitle": "Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-03-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Locally Advanced Esophageal Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 140,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "70 Years",
          "maximumAge": "85 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03289910",
          "briefTitle": "Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-19",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Atypical Chronic Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Essential Thrombocythemia", "Myelodysplastic/Myeloproliferative Neoplasm", "Myelofibrosis", "Polycythemia Vera", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07306624",
          "briefTitle": "Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-10",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-08-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 62,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "19 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07308379",
          "briefTitle": "Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-02",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["SCLC, Extensive Stage", "Toripalimab"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 1200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01186861",
          "briefTitle": "Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-03-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2015-03-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 205,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07226986",
          "briefTitle": "A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-16",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-08-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 123,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00528866",
          "briefTitle": "Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-05-14",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05214222",
          "briefTitle": "Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-09-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-09-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Esophageal Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00889187",
          "briefTitle": "Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2011-12-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06908993",
          "briefTitle": "Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-07-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Non Small Cell Lung Cancer", "MET Exon 14 Mutation"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 133,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03801304",
          "briefTitle": "Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-01-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-02-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06333314",
          "briefTitle": "Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Pancreatic Adenocarcinoma", "Ampulla of Vater Carcinoma", "Adrenocortical Carcinoma", "Neuroendocrine Carcinoma", "Soft Tissue Sarcoma", "Small Bowel Adenocarcinoma", "Duodenum Adenocarcinoma", "Gastric Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 120,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00234052",
          "briefTitle": "Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-07-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2011-11-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 51,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06545955",
          "briefTitle": "A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-10-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 250,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07244978",
          "briefTitle": "Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2032-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Esophageal Squamous Cell Carcinoma", "Neoadjuvant Therapy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 49,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05281471",
          "briefTitle": "Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-08-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Platinum-resistant Ovarian Cancer", "Platinum-refractory Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer", "High-grade Serous Ovarian Cancer", "Endometrioid Ovarian Cancer", "Ovarian Clear Cell Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 186,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02221999",
          "briefTitle": "Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Tubular Breast Cancer", "Mucinous Breast Cancer", "Invasive Ductal Breast Cancer", "Inflammatory Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 250,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02130700",
          "briefTitle": "Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-04"
          },
          "completionDateStruct": {
            "date": "2017-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Prostate Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 17,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05047536",
          "briefTitle": "KZR-261 in Subjects With Advanced Solid Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-09-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-01-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced/Metastatic Solid Tumor"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 61,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02789384",
          "briefTitle": "CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Soft-tissue Sarcomas"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 205,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06050512",
          "briefTitle": "Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-10-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed and Refractory Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04928807",
          "briefTitle": "Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-07-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-03-20",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Rectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 231,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05000892",
          "briefTitle": "Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-12-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-10-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Salivary Gland Malignant Neoplasms", "Salivary Gland Tumors"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03306121",
          "briefTitle": "TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-11-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Nasopharyngeal Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 322,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06028672",
          "briefTitle": "Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Gestational Trophoblastic Neoplasia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04585477",
          "briefTitle": "Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-04-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Non-small Cell Lung Cancer", "Non-small Cell Lung Cancer Stage I", "Non-small Cell Lung Cancer Stage II", "Non-small Cell Lung Cancer Stage III"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02020707",
          "briefTitle": "Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-02-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-07-18",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Cervical Adenocarcinoma", "Cervical Adenosarcoma", "Cervical Adenosquamous Carcinoma", "Cervical Carcinosarcoma", "Cervical Squamous Cell Carcinoma", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Endometrioid Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Carcinosarcoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Squamous Cell Carcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Malignant Female Reproductive System Neoplasm", "Malignant Ovarian Clear Cell Tumor", "Malignant Ovarian Endometrioid Tumor", "Malignant Ovarian Epithelial Tumor", "Malignant Ovarian Mucinous Tumor", "Malignant Peritoneal Neoplasm", "Malignant Solid Neoplasm", "Ovarian Carcinosarcoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Platinum-Sensitive Ovarian Carcinoma", "Primary Peritoneal Carcinosarcoma", "Primary Peritoneal Clear Cell Adenocarcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Primary Peritoneal Transitional Cell Carcinoma", "Primary Peritoneal Undifferentiated Carcinoma", "Unresectable Melanoma", "Uterine Corpus Carcinosarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 43,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04481932",
          "briefTitle": "Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-07",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "HER2-positive Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 104,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05907057",
          "briefTitle": "An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-06-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia (AML)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 245,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04595565",
          "briefTitle": "Sacituzumab Govitecan in Primary HER2-negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-10-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-03-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["HER2-negative Breast Cancer", "Triple Negative Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1332,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05764044",
          "briefTitle": "Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-03-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Cervical Cancer", "Cervix Cancer", "Cervix Neoplasm"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 365,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03838744",
          "briefTitle": "Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-05-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-11-29",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Soft Tissue Sarcoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 130,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05498155",
          "briefTitle": "Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-11-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 50,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "130 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00693992",
          "briefTitle": "Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-06-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2015-05-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Non-Small Cell Lung Cancer AJCC v7"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 210,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05427383",
          "briefTitle": "KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-04-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Stomach Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 286,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02051751",
          "briefTitle": "A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-03-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2016-08-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Neoplasms, Breast Neoplasms, Head and Neck Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 19,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06662877",
          "briefTitle": "Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-11-25",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Biliary Tract Cancer", "Second Line Treatment", "Chemotherapy", "Tyrosine Kinase Inhibitor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 206,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06697327",
          "briefTitle": "Daunorubicin + Cytarabine + Venetoclax in de Novo AML"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-02-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-08-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Leukemia, Myeloid, Acute", "Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 94,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "59 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04093362",
          "briefTitle": "Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-01-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-04-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Cholangiocarcinoma", "FGFR2 Gene Rearrangements"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00073983",
          "briefTitle": "Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-10"
          },
          "completionDateStruct": {
            "date": "2010-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Sarcoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 54,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "4 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00780494",
          "briefTitle": "Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-02"
          },
          "completionDateStruct": {
            "date": "2017-12-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Stomach Cancer", "Gastric (Stomach) Cancer", "Neoplasm of Cardioesophageal Junction", "Gastrointestinal Stromal Tumor (GIST)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 35,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04757337",
          "briefTitle": "Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-06-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-04",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Soft-tissue Sarcoma", "Metastatic Soft-tissue Sarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 214,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01926886",
          "briefTitle": "A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-11-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-07-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 102,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05456269",
          "briefTitle": "A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-07-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-08-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia", "Higher Risk Myelodysplastic Syndrome", "Chronic Myelomonocytic Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05628922",
          "briefTitle": "Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-07-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-07-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Nasopharyngeal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 198,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07291401",
          "briefTitle": "Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2026-01-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-01-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Rectal Cancer Patients"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 108,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04907227",
          "briefTitle": "Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-09-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-07-18",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Prostatic Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 81,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04541277",
          "briefTitle": "Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-09-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2022-08-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia, in Relapsed or Refractory", "Acute Myeloid Leukemia, Elderly, Unfit", "Acute Myeloid Leukemia With Positive Minimal Residual Disease"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 55,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00504257",
          "briefTitle": "Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-03"
          },
          "completionDateStruct": {
            "date": "2012-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Fallopian Tube Cancer", "Ovarian Cancer", "Malignant Tumor of Peritoneum"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01943786",
          "briefTitle": "RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-04"
          },
          "completionDateStruct": {
            "date": "2015-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer Metastatic"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06572631",
          "briefTitle": "Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-07",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-12-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Acute Myeloid Leukemia", "Recurrent Myelodysplastic Syndrome", "Refractory Acute Myeloid Leukemia", "Refractory Myelodysplastic Syndrome"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01589094",
          "briefTitle": "Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-04"
          },
          "completionDateStruct": {
            "date": "2018-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Bladder Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 51,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07251166",
          "briefTitle": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Solid Tumors"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 170,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03249870",
          "briefTitle": "Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-12-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 130,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "55 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05171166",
          "briefTitle": "Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-12-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-10-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Hepatocellular Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 18,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05889390",
          "briefTitle": "Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-02-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-08-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "HER2-negative Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 71,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00001379",
          "briefTitle": "Treatment and Natural History Study of Lymphomatoid Granulomatosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "1995-05-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-01-17",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Lymphomatoid Granulomatosis", "Granulomatosis, Lymphomatoid", "Non-Hodgkins Lymphoma", "Lymphoproliferative Disorder"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 94,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "12 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04947189",
          "briefTitle": "Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-11-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Triple Negative Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 65,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05879068",
          "briefTitle": "A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-05-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-04-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "SCLC"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 99,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06486883",
          "briefTitle": "Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Breast Cancer", "Advanced Breast Carcinoma", "Hormone Receptor Positive Breast Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06324994",
          "briefTitle": "Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-05-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Mantle Cell Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04009109",
          "briefTitle": "Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-10-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Myeloma, Multiple"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 79,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03202316",
          "briefTitle": "Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-08-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Breast Inflammatory Carcinoma", "Stage IV Breast Inflammatory Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 37,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07016126",
          "briefTitle": "D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-22",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "NSCLC (Non-small Cell Lung Cancer)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 70,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06704555",
          "briefTitle": "Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12-20",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Follicular Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07112833",
          "briefTitle": "A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-08-10",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05201547",
          "briefTitle": "Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-04-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Endometrial Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 260,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04585893",
          "briefTitle": "Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-06-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Multicentric Castleman Disease"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02939014",
          "briefTitle": "Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-11-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-02-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Hodgkin Disease", "Lymphoma, Large-Cell, Anaplastic"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 39,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02215447",
          "briefTitle": "A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Gastrointestinal Neuroendocrine Carcinomas"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 4,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03660826",
          "briefTitle": "Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-01-24",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Endometrial Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Endometrioid Adenocarcinoma", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 288,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06500026",
          "briefTitle": "A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-08-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 714,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07226999",
          "briefTitle": "A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-11-17",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2034-03-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Cancer (SCLC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 550,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02942758",
          "briefTitle": "Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-04-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-03-25",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 10,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "60 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05314998",
          "briefTitle": "Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2031-09-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Ductal Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 394,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "79 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00364013",
          "briefTitle": "PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-08-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2013-03-22",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1183,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02603679",
          "briefTitle": "Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2031-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Early-Stage Breast Carcinoma", "Estrogen Receptor Positive Tumor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 181,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04787991",
          "briefTitle": "Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-08-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-07-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Pancreatic Adenocarcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00686959",
          "briefTitle": "Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-09"
          },
          "completionDateStruct": {
            "date": "2014-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 598,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03727880",
          "briefTitle": "Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-06-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-01-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Resectable Pancreatic Ductal Adenocarcinoma (PDAC)", "Pancreatic Ductal Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "100 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06449417",
          "briefTitle": "Aurora: a Human-centered Program for Breast Cancer Patients in Chile, Easing Neoadjuvant Chemotherapy's Effects"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-03-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00107380",
          "briefTitle": "S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-11"
          },
          "completionDateStruct": {
            "date": "2015-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 86,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06574568",
          "briefTitle": "A Study of YKST02 in Participants with Relapsed or Refractory Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-06-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed or Refractory Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 70,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07170982",
          "briefTitle": "Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-10-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-10-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Endometrial Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 128,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03121846",
          "briefTitle": "Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-05-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-05-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Soft Tissue Sarcoma, Adult, Stage II"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02763579",
          "briefTitle": "A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-06-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-07-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 503,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03965468",
          "briefTitle": "Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-11-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Non-small Cell Lung Cancer", "Stage IV", "Oligometastasis"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 96,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02181413",
          "briefTitle": "A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-07-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-09-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Multiple Myeloma", "Autologous Stem Cell Transplant"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 656,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02083679",
          "briefTitle": "Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-07"
          },
          "completionDateStruct": {
            "date": "2015-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Non-Small-Cell Lung"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 15,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03426891",
          "briefTitle": "Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-03-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-06-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Glioblastoma", "Brain Tumor", "GBM"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 21,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06562920",
          "briefTitle": "Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-07-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-07-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04896320",
          "briefTitle": "Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-12-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-06-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer Stage IV"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 0,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05526924",
          "briefTitle": "Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-03-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-01-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Head and Neck Cancer", "Head and Neck Squamous Cell Carcinoma", "Head and Neck Carcinoma", "Head and Neck Cancer Stage IV", "Head and Neck Cancers - Throat"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00419159",
          "briefTitle": "Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2006-12"
          },
          "completionDateStruct": {
            "date": "2009-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 199,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02738697",
          "briefTitle": "Adjuvant Chemotherapy With FOLFOX in HCC Patients After Resection"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-01"
          },
          "completionDateStruct": {
            "date": "2021-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Hepatocellular"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 290,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03747120",
          "briefTitle": "Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-01-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["HER2-positive Breast Cancer", "Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 138,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01665417",
          "briefTitle": "Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-08"
          },
          "completionDateStruct": {
            "date": "2017-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["EGFR Positive Non-small Cell Lung Cancer", "Adenocarcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 100,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05412589",
          "briefTitle": "mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-06-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Stage III Hepatocellular Cancer (CNLC Staging)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 35,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03875313",
          "briefTitle": "Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-05-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-07-29",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Solid Tumor", "Clear Cell Renal Cell Carcinoma", "TNBC - Triple-Negative Breast Cancer", "Colorectal Cancer", "CRC", "RCC", "ccRCC"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 33,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      }
    ],
    "protocolSection.2": [
      {
        "identificationModule": {
          "nctId": "NCT05516589",
          "briefTitle": "Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-09-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Head and Neck Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04494425",
          "briefTitle": "Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-07-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-19",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced or Metastatic Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 866,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "105 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05346874",
          "briefTitle": "Neoadjuvant TACiE in Locally Advanced Gastric Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-06-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-05-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Gastric Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 37,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06124118",
          "briefTitle": "Tumor Treating Fields for Locally Advanced NSCLC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-04-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-11-15",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "22 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01012297",
          "briefTitle": "Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-11"
          },
          "completionDateStruct": {
            "date": "2015-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Uterine Corpus Sarcoma", "Stage IIIA Uterine Sarcoma", "Stage IIIB Uterine Sarcoma", "Stage IIIC Uterine Sarcoma", "Stage IVA Uterine Sarcoma", "Stage IVB Uterine Sarcoma", "Uterine Corpus Leiomyosarcoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 107,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07255404",
          "briefTitle": "A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-08",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Ductal Adenocarcinoma (PDAC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 105,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04968106",
          "briefTitle": "Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-12-07",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Resectable Sarcoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 66,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06038058",
          "briefTitle": "A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-10-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Malignancies"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 164,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02627248",
          "briefTitle": "Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-10"
          },
          "completionDateStruct": {
            "date": "2025-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05996185",
          "briefTitle": "Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-10-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["T Cell Lymphoma", "T-cell Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03165994",
          "briefTitle": "APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-02-21",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Esophageal Cancer", "GastroEsophageal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 34,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03773302",
          "briefTitle": "Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-12-27",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-03-02",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Cholangiocarcinoma", "FGFR2 Gene Mutation"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 48,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05760053",
          "briefTitle": "Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-02-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-02-18",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Toripalimab", "First-line Treatment"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 33,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01476839",
          "briefTitle": "Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-11-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-05-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Adult Hodgkin Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03009058",
          "briefTitle": "Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-05-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-08-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01829711",
          "briefTitle": "Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-04-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-04-29",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Leukemia, Hairy Cell"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "100 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05628038",
          "briefTitle": "The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-11-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Rectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 93,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07059338",
          "briefTitle": "Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-07-11",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2028-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["HER2 Positive", "Colorectal Cancer (CRC)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 34,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06775743",
          "briefTitle": "ORIENT-31 Regimen in Combination with SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["NSCLC (advanced Non-small Cell Lung Cancer)", "EGFR Mutation Positive Advanced Non Small Cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 53,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04493164",
          "briefTitle": "CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-12-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-06-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Acute Myeloid Leukemia With Gene Mutations", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03006614",
          "briefTitle": "PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-04"
          },
          "completionDateStruct": {
            "date": "2023-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Breast Cancer Model", "Effects of Chemotherapy", "Breast Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 320,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": true,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03476239",
          "briefTitle": "Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-04-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Lymphoblastic Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 121,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04956692",
          "briefTitle": "Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-08-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-10-14",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 531,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02595892",
          "briefTitle": "Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2016-08-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-08-05",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Serous Tumor", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 70,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06253871",
          "briefTitle": "A Phase 1/1b Study of IAM1363 in HER2 Cancers"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-03-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-03",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["HER2 Mutation-Related Tumors", "HER2", "HER2-positive Breast Cancer", "HER2 + Breast Cancer", "Brain Metastases From Solid Tumors", "Brain Metastases From HER2 and Breast Cancer", "CNS Metastases", "HER2-Positive Solid Tumors", "NSCLC (Non-small Cell Lung Cancer)", "HER2-positive Bladder Cancer", "HER2-positive Colorectal Cancer", "HER2 + Gastric Cancer", "HER2-positive Gastroesophageal Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 243,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01963052",
          "briefTitle": "ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-11-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-07-08",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Urothelial Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 93,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04974047",
          "briefTitle": "Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-08-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-10-25",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Resectable Esophageal Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 70,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03350126",
          "briefTitle": "iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-12-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Cancer Colorectal"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 57,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04476576",
          "briefTitle": "Aerobic Exercise is Cardio-protective in Hemato-oncological Disease and New-onset Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-03-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Cardiotoxicity", "Systolic Dysfunction", "Exercise, Aerobic"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 38,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01664117",
          "briefTitle": "An Observational Study in Clinical Practice Management of Patients With Biological Drugs in Monotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-06"
          },
          "completionDateStruct": {
            "date": "2013-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Rheumatoid Arthritis"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 210,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03718117",
          "briefTitle": "Descriptive Observational Study ALK-2016-CPHG"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-01-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-07-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["NSCLC", "Crizotinib", "ALK Gene Rearrangement or ROS1 Gene Rearrangement"]
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 73,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05929768",
          "briefTitle": "Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2033-04",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Early Stage Triple-Negative Breast Carcinoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 2400,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01402284",
          "briefTitle": "Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-07-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-09-24",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "99 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00695409",
          "briefTitle": "Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2008-03-18",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2017-03-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 122,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02910063",
          "briefTitle": "Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-01-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2020-03-12",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "B-Cell Non Hodgkin Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 41,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06746116",
          "briefTitle": "A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-11-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced or Recurrent Endometrial Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 45,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "130 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01454089",
          "briefTitle": "A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-10"
          },
          "completionDateStruct": {
            "date": "2014-11",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Urologic Neoplasms", "Metastatic Bladder Cancer", "Urinary Tract Neoplasms"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 183,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02625610",
          "briefTitle": "Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-12-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2021-06-03",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 499,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06292689",
          "briefTitle": "A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-03-22",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-03-22",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Vulvar and Vaginal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06012435",
          "briefTitle": "A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-02-21",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-03-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Non-Small-Cell Lung"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 703,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00602797",
          "briefTitle": "Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-12-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2014-08-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Recurrent Non-Small Cell Lung Carcinoma", "Stage IV Non-Small Cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03221426",
          "briefTitle": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-10-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-04-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Gastric Cancer", "Gastroesophageal Junction Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1007,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00392990",
          "briefTitle": "Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2007-02-06"
          },
          "completionDateStruct": {
            "date": "2013-05-28",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 25,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06770582",
          "briefTitle": "Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2032-02-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Non-Muscle Invasive Bladder Urothelial Carcinoma", "Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma", "Stage I Bladder Cancer AJCC v8"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 160,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02414685",
          "briefTitle": "First Line TIP in Poor Prognosis TGCTs."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-04"
          },
          "completionDateStruct": {
            "date": "2020-06",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Germ Cell Tumor"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 19,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04807140",
          "briefTitle": "Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-07-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-01-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Head and Neck Squamous Cell Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 57,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "80 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06340568",
          "briefTitle": "A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-06-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Endometrial Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 504,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01425008",
          "briefTitle": "Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2011-09-15",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-10-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Melanoma", "Metastatic Melanoma", "Solid Tumor", "Neoplasm"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 149,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01648608",
          "briefTitle": "Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2012-01"
          },
          "completionDateStruct": {
            "date": "2013-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 600,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04137640",
          "briefTitle": "Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-07-19",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-05-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 152,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04988191",
          "briefTitle": "Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-12-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-12-24",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 44,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03117920",
          "briefTitle": "A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-04-10",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-07-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Pancreatic Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 19,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05106296",
          "briefTitle": "Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-02-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-09",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ependymoma", "Medulloblastoma", "Glioblastoma", "Primary Brain Tumor"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 37,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "6 Years",
          "maximumAge": "25 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03907826",
          "briefTitle": "PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-03-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Recurrent Nasopharyngeal Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 212,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05664243",
          "briefTitle": "A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Glioblastoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 4,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04370925",
          "briefTitle": "Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-06-04",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-04-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 688,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05502913",
          "briefTitle": "Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-09-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 80,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05834413",
          "briefTitle": "Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-05-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2026-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 367,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "74 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03573024",
          "briefTitle": "Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-11-28",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 36,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "59 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT07125183",
          "briefTitle": "Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2029-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Sarcoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 20,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "65 Years",
          "maximumAge": "100 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05464329",
          "briefTitle": "Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-01-03",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-10-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Large B-cell Lymphoma", "High-grade B-cell Lymphoma", "Transformed B-Cell Lymphoma", "Follicular Lymphoma Grade 3B"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 24,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01049945",
          "briefTitle": "Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2015-09-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Refractory Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 70,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04751877",
          "briefTitle": "Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years)."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-07-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-08-17",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Multiple Myeloma", "Myeloma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 270,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "65 Years",
          "maximumAge": "79 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04564157",
          "briefTitle": "New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-01-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2031-04-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Non-Small Cell Lung Cancer", "Adjuvant Chemotherapy"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 210,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02541903",
          "briefTitle": "Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-10"
          },
          "completionDateStruct": {
            "date": "2020-04",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Penile Squamous Cell Carcinoma (PSCC)"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 8,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "MALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04414566",
          "briefTitle": "Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-06-01",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2025-05-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Nasopharyngeal Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 562,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06737822",
          "briefTitle": "Upfront Surgery Vs Induction Chemotherapy Followed By Surgery In Oral Cancers:"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2029-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Oral Cancer", "Head and Neck Neoplasms"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 346,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05457829",
          "briefTitle": "Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of First Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-12-30",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-07-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Rhabdomyosarcoma, Child"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 88,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "6 Months",
          "maximumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01193842",
          "briefTitle": "Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2010-10-06",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-05-19",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["AIDS-Related Plasmablastic Lymphoma", "AIDS-Related Primary Effusion Lymphoma", "Ann Arbor Stage I Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage I Grade 3 Follicular Lymphoma", "Ann Arbor Stage II Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage III Grade 3 Follicular Lymphoma", "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IV Grade 3 Follicular Lymphoma", "HIV Infection", "Plasmablastic Lymphoma", "Primary Effusion Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Grade 3 Follicular Lymphoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 107,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06612151",
          "briefTitle": "A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-12-17",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2030-12-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 438,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02554812",
          "briefTitle": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-11-09",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-03-23",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Advanced Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 409,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05009966",
          "briefTitle": "Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-09-16",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-06",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Advanced Solid Tumor", "Gastric Cancer (GC)", "Gastroesophageal Junction (GEJ) Cancer", "Pancreatic Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 272,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02112045",
          "briefTitle": "A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-01-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2019-09-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 90,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03901339",
          "briefTitle": "Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-05-08",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-10-20",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Metastatic Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 543,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06022003",
          "briefTitle": "Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2024-01-13",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-10",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["AML, Adult", "Refractory AML", "Relapsed Adult AML", "FLT3-TKD Mutation", "FLT3-ITD"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 33,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01851369",
          "briefTitle": "TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-07-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2023-08-01",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Lymphomas", "Solid Tumors", "NSCLC", "Metastatic Colon Carcinoma", "Granulosa Cell Ovarian Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 93,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "120 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02655601",
          "briefTitle": "Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-09-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-31",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["High Grade Glioma", "Astrocytoma, Grade III", "Glioblastoma"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 177,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04175769",
          "briefTitle": "A Nutritional Supplement to Support People With Non-small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-12-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2025-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non-small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 9,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05224141",
          "briefTitle": "Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-03-24",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-06-07",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 460,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00626639",
          "briefTitle": "A Study of Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy and Concurrent Chemotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2005-07"
          },
          "completionDateStruct": {
            "date": "2015-07",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": ["Mucositis", "Head and Neck Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 5,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04401995",
          "briefTitle": "Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2020-09-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-08-16",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Melanoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 9,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03606239",
          "briefTitle": "NSCLC Isotoxic Hypofractionated Chemoradiotherapy"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-02-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-02-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Carcinoma, Non-Small-Cell Lung"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03281954",
          "briefTitle": "Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2017-12-19",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-11-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Triple Negative Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 1550,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04664972",
          "briefTitle": "Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2018-11-23",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2022-11-26",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Triple Negative Breast Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 212,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02402972",
          "briefTitle": "A Multi-center Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-02"
          },
          "completionDateStruct": {
            "date": "2022-02",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Colorectal Cancer", "Metastasis"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 700,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05683977",
          "briefTitle": "A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-11-14",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-03-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Small Cell Lung Carcinoma"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 254,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05514275",
          "briefTitle": "Radiotherapy Combined With Endostatin and Capecitabine for NPC"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-08-01",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-08-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Nasopharyngeal Carcinoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 41,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "65 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05578326",
          "briefTitle": "Study of Trilaciclib and Lurbinectidin"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2022-10-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-12-25",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Lung Cancer", "Small-cell Lung Cancer"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01935778",
          "briefTitle": "Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2013-10-02",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2028-06-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Gastric Cancer, Adjuvant Chemotherapy, XO"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 286,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "20 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06751485",
          "briefTitle": "JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2025-01-15",
            "type": "ESTIMATED"
          },
          "completionDateStruct": {
            "date": "2027-12-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Ovarian Cancer", "Primary Peritoneal", "Fallopian Tube Cancers"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 430,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "FEMALE",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT05073250",
          "briefTitle": "IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-12-31",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-11-01",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Inert Non Hodgkin's Lymphoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 40,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04699838",
          "briefTitle": "Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-04-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-11",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Extensive Stage Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 30,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04776148",
          "briefTitle": "Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2021-03-29",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-09-27",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Colorectal Neoplasms"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 563,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02315326",
          "briefTitle": "Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2014-12",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2026-12",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": ["Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)", "Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)"]
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 109,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT03890068",
          "briefTitle": "Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-04-11",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-05-30",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Soft Tissue Sarcoma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 48,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT01017874",
          "briefTitle": "A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2009-11"
          },
          "completionDateStruct": {
            "date": "2014-10",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 236,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT04197076",
          "briefTitle": "Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2019-02-25",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2024-12-31",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Non Small Cell Lung Cancer"
        },
        "designModule": {
          "studyType": "OBSERVATIONAL",
          "enrollmentInfo": {
            "count": 200,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "75 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT00047840",
          "briefTitle": "This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer."
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2002-10"
          },
          "completionDateStruct": {
            "date": "2006-09",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 129
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT06049290",
          "briefTitle": "A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2023-10-20",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2027-05-20",
            "type": "ESTIMATED"
          }
        },
        "conditionsModule": {
          "conditions": "Relapsed/Refractory Multiple Myeloma"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 342,
            "type": "ESTIMATED"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years"
        }
      },
      {
        "identificationModule": {
          "nctId": "NCT02440568",
          "briefTitle": "AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients"
        },
        "statusModule": {
          "startDateStruct": {
            "date": "2015-06-05",
            "type": "ACTUAL"
          },
          "completionDateStruct": {
            "date": "2018-11-30",
            "type": "ACTUAL"
          }
        },
        "conditionsModule": {
          "conditions": "Acute Myeloid Leukemia"
        },
        "designModule": {
          "studyType": "INTERVENTIONAL",
          "enrollmentInfo": {
            "count": 22,
            "type": "ACTUAL"
          }
        },
        "eligibilityModule": {
          "healthyVolunteers": false,
          "sex": "ALL",
          "minimumAge": "18 Years",
          "maximumAge": "70 Years"
        }
      }
    ]
  }
}
